ReviewFrontiers in medicine2022
SARS-CoV-2 variants: Impact on biological and clinical outcome.
Review in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Severity of COVID-19 Omicron Variants: A Global Systematic Review.Infectious diseases and therapy · 2026Pooled it
- Diversity and clinical correlations of SARS-CoV-2 variant during the introduction of the Delta variant in Guatemala.Access microbiology · 2026Article
- Analysis of the prevalence, spread, and mutation patterns of SARS-CoV-2 variants: data from COVID-19 testing expansion strategy study in salvador, Northeast Brazil.Scientific reports · 2025Article
- Differential responses of lung and intestinal microbiota to SARS-CoV-2 infection: a comparative study of the Wuhan and Omicron strains in K18-hACE2 Tg mice.Laboratory animal research · 2025Article
- SARS-CoV-2 Vaccine-Induced Humoral Immunity in Immunocompetent European Adults: A Systematic Review.Microorganisms · 2025Review
- Effect of Exportin 1/XPO1 Nuclear Export Pathway Inhibition on Coronavirus Replication.Viruses · 2025Article
- COVID-19 symptom severity and duration among outpatients, July 2021-May 2023: The PROTECT observational study.PloS one · 2025Observational
- Mice carrying the full-length human immunoglobulin loci produce antigen-specific human antibodies with the lambda light chain.iScience · 2024Article
- Article
- Effect of exportin 1/XPO1 nuclear export pathway inhibition on coronavirus replication.bioRxiv : the preprint server for biology · 2024Article
- Late Recurrence of C3 Glomerulopathy After SARS-CoV-2 Infection in a Long-Term Kidney Transplant Recipient: A Case Report.The American journal of case reports · 2024Article
- Emergence of SARS-CoV-2 omicron variant JN.1 in Tamil Nadu, India - Clinical characteristics and novel mutations.Scientific reports · 2024Article
- Detection and Characterisation of SARS-CoV-2 in Eastern Province of Zambia: A Retrospective Genomic Surveillance Study.International journal of molecular sciences · 2024Article
- Emergence of SARS-CoV-2 Omicron Variant JN.1 in Tamil Nadu, India - Clinical Characteristics and Novel Mutations.medRxiv : the preprint server for health sciences · 2024Article
- Characteristics of infections with ancestral, Beta and Delta variants of SARS-CoV-2 in the PHIRST-C community cohort study, South Africa, 2020-2021.BMC infectious diseases · 2024Article
- SARS-CoV-2 strains and clinical profiles of COVID-19 patients in a Southern Brazil hospital.Frontiers in immunology · 2024Article
- Neuroprotective Agents with Therapeutic Potential for COVID-19.Biomolecules · 2023Review
- Article
- Animal models to study the neurological manifestations of the post-COVID-19 condition.Lab animal · 2023Review
- NGS implementation for monitoring SARS-CoV-2 variants in Chicagoland: An institutional perspective, successes and challenges.Frontiers in public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) that was first identified in December 2019, in Wuhan, China was found to be the etiological agent for a novel respiratory infection that led to a Coronavirus Induced Disease named COVID-19. The disease spread to pandemic magnitudes within a few weeks and since then we have been dealing with several waves across the world, due to the emergence of variants and novel mutations in this RNA virus. A direct outcome of these variants apart from the spike of cases is the diverse disease presentation and difficulty in employing effective diagnostic tools apart from confusing disease outcomes. Transmissibility rates of the variants, host response, and virus evolution are some of the features found to impact COVID-19 disease management. In this review, we will discuss the emerging variants of SARS-CoV-2, notable mutations in the viral genome, the possible impact of these mutations on detection, disease presentation, and management as well as the recent findings in the mechanisms that underlie virus-host interaction. Our aim is to invigorate a scientific debate on how pathogenic potential of the new pandemic viral strains contributes toward development in the field of virology in general and COVID-19 disease in particular.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.